Transcriptomic analysis reveals a zinc homeostasis gene signature predicts survival in breast cancer, suggesting utility for risk stratification and immunotherapy selection.
This study was conducted to explore the role of zinc homeostasis in breast cancer (BC). We identified a gene signature in BC comprising nine key zinc homeostasis-related genes ( CCDC74B , ELOVL2 , FAM234B , FUT3 , KCNJ11 , NXPH4 , RIBC1 , UPK2 , and WNK4 ), from which we constructed a risk score model. Cox regression analyses confirmed the independent prognostic value of the risk score. BC patients with low-risk scores had significantly higher overall survival rates. The high-risk group exhibited lower immune cell infiltration but significantly decreased tumor immune dysfunction and exclusion (TIDE) scores, suggesting a greater likelihood of benefiting from immunotherapy. Significant differences were observed between the high- and low-risk groups in terms of biological pathways and the carcinogenic process. A single-cell analysis identified CD8 + T cells as the most abundant cell population in the tumor tissue. A methylation analysis revealed that methylation levels of eight genes differed significantly between the disease and control groups. Quantitative real-time PCR and western blotting analyses confirmed significant increases in the mRNA and protein levels of the genes CCDC74B , ELOVL2 , FAM234B , RIBC1 , and UPK2 . In summary, we established a novel zinc homeostasis-related gene signature for BC that robustly stratifies patients into distinct risk groups with different characteristics and survival outcomes.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: